PCAS: RELEASE OF THE 2022 UNIVERSAL REGISTRATION DOCUMENT (URD)
28 April 2023 - 6:00PM
PCAS: RELEASE OF THE 2022 UNIVERSAL REGISTRATION DOCUMENT (URD)
RELEASE OF THE
2022 UNIVERSAL
REGISTRATION DOCUMENT (URD)
Ecully, April
28,
2023
The PCAS Universal Registration Document 2022,
which includes the annual financial report, was filed with France's
Financial Markets Authority, in ESEF format (European Single
Electronic Format), on April 27, 2023, under number D.23-0356.
This document contains:
- The 2022 annual financial
report
- The Board of Directors' corporate
governance report in accordance with Section L.225-37 of France's
Commercial Code
- The statutory auditors’
reports
- The information relating to the
statutory auditors' fees
This document in French version is available in accordance with
the applicable regulatory conditions.
It may be consulted:
- At PCAS headquarters: 21 chemin de
la Sauvegarde, 21 Ecully Parc, CS 33167, 69134 Ecully, France
- On the company website:
www.pcas.com
- On the AMF website:
www.amf-france.org
|
NEXT
FINANCIAL DISCLOSURE: |
Net Sales as of
June 30, 2023 – July 27, 2023 |
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With about 11% of its net sales earmarked for R&D
and a large international footprint, PCAS is the preferred
industrial partner for market-leading major global groups. Boasting
especially high standards, the company offers a growing range of
proprietary products and solutions in leading-edge segments. PCAS
generated net sales of €226.4 million in 2022 and employs nearly
1200 people in six countries.
To find out more about PCAS: www.pcas.com
PCAS |
Newcap |
Jean-Louis Martin / Eric
Moissenot |
Emmanuel Huynh / Louis-Victor DelouvrierFinancial
communication and investor relations |
Tél. : +33 1 69 79 60 00 www.pcas.com |
Tél. : +33 1 44 71 98 53pcas@newcap.eu |
PCAS (EU:PCA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
PCAS (EU:PCA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024